Seqirus Inc
Seqirus Inc received $121.6M in federal prime contract obligations in the 12 months ending Oct 5, 2026, up 41.2% from $86.2M the year before, and $732.8M since FY2022. Its largest customer is the Department of Health and Human Services.
See 3 contracts ending in the next 18 months ↓Contractor details
- Unique Entity ID (UEI)
- Z6N1LJ2RD6E3
- CAGE code
- 7L0Y8
- Headquarters
- Holly Springs, NC
- Business size
- Other Than Small Business
As recorded on this UEI's most recent prime contract action in USAspending.gov. Confirm current registration and certifications in SAM.gov.
Obligations by fiscal year
Net prime contract obligations by federal fiscal year.
Markets where it ranks top 10
Agency and NAICS markets where this UEI is one of the ten largest primes in the latest 12 months.
Top agencies
Funding agencies ranked by obligations since FY2022.
| Funding agency | Latest 12 mo | Since FY2022 |
|---|---|---|
| Department of Health and Human Services | $121.6M | $732.8M |
Top NAICS codes
Industry codes agencies recorded on this contractor's awards, since FY2022.
What it sells
Product and service codes (PSC) on this contractor's awards, since FY2022.
| PSC | Description | Since FY2022 |
|---|---|---|
| AD61 | R&D- Defense other: Construction (Basic Research) | $612.2M |
| 6505 | Drugs and Biologicals | $102.8M |
| AN12 | Health R&D services; Health Care services; Applied Research | $31.3M |
Contracts ending in the next 18 months
This contractor's largest awards whose current period of performance ends soon. Options and extensions often move these dates.
| Award | Agency | Obligated | Current end |
|---|---|---|---|
| 75A50126F61013 | Department of Health and Human Services TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO CONFIRM IMMUNOGENICITY SUPERIORITY OF A NEW VACCINE STRAIN VERSUS THE PROTOTYPE STRAIN | $450K | May 8, 2027 |
| 75A50124F61009 | Department of Health and Human Services THE PURPOSE OF THIS REQUIREMENT IS TO PROVIDE MEDICAL COUNTERMEASURES (MCMS), SUCH AS VACCINES AND ADJUVANTS, FOR PANDEMIC PREPAREDNESS AND RESPONSE OR AS REQUIRED IN RESPONSE TO… | $396K | May 21, 2027 |
| 75A50124F61008 | Department of Health and Human Services THE PURPOSE OF THIS REQUIREMENT IS TO PROVIDE MEDICAL COUNTERMEASURES (MCMS), SUCH AS VACCINES AND ADJUVANTS, FOR PANDEMIC PREPAREDNESS AND RESPONSE OR AS REQUIRED IN RESPONSE TO… | $23.3M | May 21, 2027 |
Recent awards
This contractor's newest prime contract awards, most recent first.
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| 75A50126F61015 | Department of Health and Human Services FORMULATION AND FILLING OF MF59-ADJUVANTED CELL-BASED A/HENAN/4-10CNIC/2022 (H3N8)-LIKE VACCINE AND CLINICAL TRIAL IMPLEMENTATION | $42.8M | Sep 29, 2026 |
| 75A50126F61014 | Department of Health and Human Services MANUFACTURE AND STABILITY STUDIES OF THIMEROSAL-FREE PANDEMIC INFLUENZA VACCINE MULTIDOSE VIALS (MDVS) | $2.1M | Sep 24, 2026 |
| 75A50126F61012 | Department of Health and Human Services EXTRACTABLE/ LEACHABLE & STABILITY STUDY TO SUPPORT LONG-TERM BULK STORAGE IN SINGLE-USE CONTAINERS | $565K | May 8, 2026 |
| 75A50126F61013 | Department of Health and Human Services TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO CONFIRM IMMUNOGENICITY SUPERIORITY OF A NEW VACCINE STRAIN VERSUS THE PROTOTYPE STRAIN | $450K | Apr 3, 2026 |
| 75A50124F61011 | Department of Health and Human Services THE PURPOSE OF THIS TASK ORDER IS TO PERFORM A SHORT-TERM PHYSICAL AND CHEMICAL COMPATIBILITY (PC) STUDY ON THE ANTIGEN AND MF59 DOSING COMBINATIONS TO SUPPORT OF THE INTENDED… | $24K | Sep 19, 2024 |
| 75A50124F61010 | Department of Health and Human Services THIS TASK ORDER ESTABLISHES SERVICES FOR H5 PANDEMIC READINESS FOR ACQUISITION OF MEDICAL COUNTERMEASURES (MCMS) FOR PANDEMIC INFLUENZA AND EMERGING DISEASES PREPAREDNESS AND… | $261K | May 3, 2024 |
| 75A50124F61008 | Department of Health and Human Services THE PURPOSE OF THIS REQUIREMENT IS TO PROVIDE MEDICAL COUNTERMEASURES (MCMS), SUCH AS VACCINES AND ADJUVANTS, FOR PANDEMIC PREPAREDNESS AND RESPONSE OR AS REQUIRED IN RESPONSE TO… | $597K | Feb 21, 2024 |
| 75A50124F61009 | Department of Health and Human Services THE PURPOSE OF THIS REQUIREMENT IS TO PROVIDE MEDICAL COUNTERMEASURES (MCMS), SUCH AS VACCINES AND ADJUVANTS, FOR PANDEMIC PREPAREDNESS AND RESPONSE OR AS REQUIRED IN RESPONSE TO… | $29K | Feb 21, 2024 |
Prime contracts (award types A–D) from USAspending.gov through Oct 5, 2026. Subcontracts are not included. Net obligations include deobligations and corrections.
Ready to connect your pursuit work?
GovEagle gives BD directors, capture managers, and proposal teams one AI workspace from pipeline through proposal, with CMMC/FedRAMP Certified compliance built in.